Cardiovascular Systems Inc. (NASDAQ:CSII) insider Laura Gillund sold 1,268 shares of Cardiovascular Systems stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $26.79, for a total value of $33,969.72. Following the completion of the transaction, the insider now owns 69,541 shares in the company, valued at $1,863,003.39. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Cardiovascular Systems Inc. (NASDAQ:CSII) traded down 1.97% during mid-day trading on Monday, reaching $26.39. The company’s stock had a trading volume of 250,017 shares. The firm’s market capitalization is $872.53 million. Cardiovascular Systems Inc. has a 52 week low of $7.50 and a 52 week high of $27.38. The firm’s 50 day moving average price is $24.04 and its 200 day moving average price is $20.81.

Cardiovascular Systems (NASDAQ:CSII) last posted its earnings results on Wednesday, October 26th. The medical device company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.13. Cardiovascular Systems had a negative return on equity of 30.19% and a negative net margin of 24.24%. The firm had revenue of $49.80 million for the quarter, compared to analysts’ expectations of $205.50 million. During the same period last year, the firm earned ($0.41) EPS. The firm’s revenue was up 13.5% compared to the same quarter last year. On average, analysts anticipate that Cardiovascular Systems Inc. will post ($0.21) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Cardiovascular Systems (NASDAQ:CSII)

A number of hedge funds have recently bought and sold shares of CSII. Gamco Investors INC. ET AL boosted its stake in Cardiovascular Systems by 0.3% in the second quarter. Gamco Investors INC. ET AL now owns 36,400 shares of the medical device company’s stock valued at $669,000 after buying an additional 100 shares in the last quarter. Cutler Group LP boosted its stake in Cardiovascular Systems by 4.7% in the second quarter. Cutler Group LP now owns 7,787 shares of the medical device company’s stock valued at $143,000 after buying an additional 350 shares in the last quarter. BlackRock Group LTD boosted its stake in Cardiovascular Systems by 4.1% in the third quarter. BlackRock Group LTD now owns 12,172 shares of the medical device company’s stock valued at $289,000 after buying an additional 477 shares in the last quarter. BlackRock Advisors LLC boosted its stake in Cardiovascular Systems by 3.3% in the second quarter. BlackRock Advisors LLC now owns 15,089 shares of the medical device company’s stock valued at $277,000 after buying an additional 486 shares in the last quarter. Finally, California State Teachers Retirement System boosted its stake in Cardiovascular Systems by 1.0% in the third quarter. California State Teachers Retirement System now owns 67,511 shares of the medical device company’s stock valued at $1,603,000 after buying an additional 700 shares in the last quarter. Hedge funds and other institutional investors own 69.77% of the company’s stock.

Several research analysts have weighed in on the company. Zacks Investment Research upgraded Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Monday, August 8th. Needham & Company LLC lifted their price target on Cardiovascular Systems from $23.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, August 4th. Leerink Swann restated an “outperform” rating and issued a $30.00 price target on shares of Cardiovascular Systems in a research note on Tuesday, November 15th. Feltl & Co. upgraded Cardiovascular Systems from a “buy” rating to a “strong-buy” rating and set a $30.00 price target on the stock in a research note on Thursday, October 27th. Finally, Bank of America Corp. upgraded Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a research note on Thursday, August 4th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $27.50.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

5 Day Chart for NASDAQ:CSII

Receive News & Stock Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related stocks with our FREE daily email newsletter.